Heron Therapeutics (HRTX) Misses Q1 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Heron Therapeutics (HRTX) Misses Q1 EPS by 15c

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates

May 9, 2022 4:05 PM EDT

- ZYNRELEF® unit demand increased 68% in the first quarter compared to the prior quarter -

- Centers for Medicare and Medicaid Services approved a 3-year transitional pass-through status for ZYNRELEF beginning April 1, 2022 to support separate reimbursement outside of the surgical bundle payment for the HOPD setting of care -

- Oncology Care Franchise net revenue of $22.4 million in Q1 2022, a 13% increase over the prior quarter -

- Oncology Care Franchise full-year 2022 net revenue expected to be $89 million to $93 million... More